Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, Can Jin, Wanhong Xu, Christopher Argent, Yulia Kushnareva, Colin Powers, Karen Stegman, Jia Liu, Huimin Xie, Changxu Xu, Yimei Bao, Lijun Xu, Yuren Zhang, Haigang Yang, Shengdian Qian, Yong Hu, Jianping Shao, Can Zhang, Tingting Li, Yi Li, Na Liu, Zhenhao Lin, Shanbo Wang, Chao Wang, Wei Shen, Yuanlong Lin, Dan Shu, Zhenhong Zhu, Olivia Kotoi, Lisa Kerwin, Qing Han, Ludmila Chumakova, John R. Teijaro, Mike A. Royal, Mark Brunswick, Robert D. Allen, Henry Ji, Hongzhou Lu, Xiao Xu
Abstract
(Med 5, 42–61.e1–e23; January 12, 2024) In our originally published article, we inadvertently omitted a value in the table of Figure 4A. The cell in column “2000 mg” and row “Cmax (ng/mL)a” contained only the standard deviation (± 5050), while the mean value (17800) was missing. The text within the cell has been corrected online from “± 5050” to “17800 ± 5050,” and the full revised figure appears below. The authors apologize for this error and any confusion it may have caused. Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Mao et al.MedJanuary 4, 2024In BriefMao et al. discovered and developed a next-generation antiviral, olgotrelvir, as a standalone treatment for COVID-19 without ritonavir. Olgotrelvir, with a dual mechanism of action targeting SARS-CoV-2 Mpro and human cathepsin L, significantly inhibited virus replication in an animal model and in COVID-19 patients by oral administration. Full-Text PDF Open Access